Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

EAST BRUNSWICK, N.J., Aug. 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six months ended June 30, 2011, which are reflective of significant investments in the U.S. launch of KRYSTEXXA® (pegloticase).  Savient ended the quarter with $240.3 million in cash and short-term investments, a decrease of $27.7 million for the quarter.  For the second quarter of 2011, the Company had a net loss of $30.2 million, or $0.43 per share, on total revenues of $2.0 million.  This compares with a net loss of $5.0 million, or $0.07 per share, on total revenues of $1.0 million for the same period in 2010.  The net loss for the first six months of 2011 was $43.8 million, or $0.63 per share on total revenues of $3.3 million compared with a net loss of $13.3 million, or $0.20 per share, on total revenues of $2.1 million for the same period in 2010.  

"The second quarter was a busy and exciting time at Savient and we are off to a promising start as we continue to build and develop a market for the first and only FDA approved treatment for Refractory Chronic Gout," said John H. Johnson, Chief Executive Officer and President of Savient.  "By making key investments to build out our capabilities and implement new programs to support the commercialization of KRYSTEXXA, we believe we are effectively laying the groundwork to position KRYSTEXXA for success and build shareholder value."Savient also today announced the results from a Company commissioned comprehensive U.S. Refractory Chronic Gout (RCG) market research study evaluating the market size of the RCG population. This market research study was sponsored by the Company in conjunction with a leading independent life sciences consulting firm.  The results of the study indicate that there are approximately 120,000 RCG patients in the U.S., w
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
2. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
3. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
4. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
5. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
6. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
7. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
8. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
10. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
11. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
(Date:4/25/2015)... 26, 2015 Avid Collector Andrew Hawley ... Rolling Stones Greensboro Coliseum concert posters. The concert was ... the Stone's Second American Tour. , According to ... out of Baltimore, Maryland. This poster blank was used ... southern cites. Globe uses garish lettering and colors on ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 The ... vaginal mesh lawsuits filed against C.R. Bard, Inc. ... Court, Southern District of West Virginia. According to ... Conference was convened that day, after certain defendants ... Form Complaint. The Order directed that any Preliminary ...
(Date:4/25/2015)... BWI (PRWEB) April 25, 2015 An ... celebrated three months of successfully welcoming visitors to the ... 2015. , As part of a major construction ... airport was completely redesigned to speed up arrivals. ... process of getting out of the airport and onto ...
(Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse ... case with the Miami Dolphins and Richie Incognito, or off the ... Rice domestic abuse case. In a recent episode of SCI ... implications of locker room culture on teams. He examines what worked ... do to improve the locker room as a work place. ...
(Date:4/24/2015)... April 24, 2015 Constellations Recovery celebrates ... in Westchester County. Just 35 miles from New York ... back into everyday life while recovering from addiction. The ... 2015, will allow therapists, doctors and treatment centers to ... more about the opportunities offered by Constellations Recovery.,  , ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
... able to stop or even slightly improve the progression ... to implant // embryonic cells into their brains, say ... that helps control movement. People with Parkinson’s don’t produce ... in people with the condition. ,Researchers compared 20 ...
... of Pittsburgh Medical Center treated 33 prostate cancer patients, ... Patients received the same radiation doses that patients in ... study show the elderly patients had a five-year survival ... patients experienced no unusual or prolonged breaks in treatment ...
... to cancer-causing pollutants found in the air, report researchers ... .Past studies in mice have shown exposure to pollutants ... the fact the placenta filters out most of the ... in humans. ,Researchers collected blood samples from 265 ...
... United States suffer from erectile dysfunction. This causes a ... and weight loss // , obese men with erectile ... say researchers. ,Researchers, conducted a study to determine ... increase in physical activity, would improve obese men’s erectile ...
... not decrease, but may increase, the risk for dementia ... an association between postmenopausal estrogen use and lower risk ... estrogen plus progestin in women aged 65 to 79 ... estrogen-only trial, researchers found 47 participants were diagnosed with ...
... 20s could reduce the risk of developing high blood pressure ... with spikes in blood pressure are more likely to have ... ,Specialists say assessing blood pressure changes in response to stress ... risk of high blood pressure. In a large study more ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: